Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Frail Elderly | 67 | 2025 | 785 | 11.830 |
Why?
|
Geriatric Assessment | 53 | 2024 | 1429 | 9.280 |
Why?
|
Medicare | 70 | 2025 | 6823 | 4.650 |
Why?
|
Dementia | 21 | 2024 | 2744 | 3.700 |
Why?
|
Activities of Daily Living | 25 | 2024 | 2415 | 3.370 |
Why?
|
Independent Living | 18 | 2024 | 585 | 3.270 |
Why?
|
Aged | 206 | 2025 | 171114 | 2.430 |
Why?
|
Skilled Nursing Facilities | 7 | 2025 | 410 | 2.190 |
Why?
|
Insurance Claim Review | 8 | 2024 | 745 | 1.950 |
Why?
|
Delirium | 9 | 2025 | 1707 | 1.870 |
Why?
|
Heart Valve Prosthesis Implantation | 9 | 2021 | 1566 | 1.780 |
Why?
|
Aortic Valve Stenosis | 16 | 2024 | 2023 | 1.760 |
Why?
|
Sarcopenia | 6 | 2024 | 378 | 1.730 |
Why?
|
Aged, 80 and over | 92 | 2025 | 59488 | 1.730 |
Why?
|
Antipsychotic Agents | 7 | 2023 | 3074 | 1.720 |
Why?
|
Pneumonia | 5 | 2022 | 2157 | 1.700 |
Why?
|
Republic of Korea | 13 | 2025 | 588 | 1.690 |
Why?
|
Atrial Fibrillation | 14 | 2024 | 5189 | 1.620 |
Why?
|
Hypertension | 17 | 2023 | 8626 | 1.600 |
Why?
|
Cardiovascular Diseases | 21 | 2024 | 15651 | 1.500 |
Why?
|
United States | 98 | 2025 | 72898 | 1.480 |
Why?
|
Cholinesterase Inhibitors | 3 | 2024 | 241 | 1.300 |
Why?
|
Humans | 264 | 2025 | 765956 | 1.280 |
Why?
|
Antihypertensive Agents | 12 | 2023 | 2033 | 1.240 |
Why?
|
Memantine | 2 | 2024 | 110 | 1.210 |
Why?
|
Patient Discharge | 10 | 2024 | 3461 | 1.200 |
Why?
|
Aortic Valve | 11 | 2021 | 1968 | 1.200 |
Why?
|
Blood Pressure | 16 | 2023 | 8532 | 1.180 |
Why?
|
Male | 139 | 2025 | 363691 | 1.140 |
Why?
|
Blood Pressure Determination | 6 | 2023 | 647 | 1.130 |
Why?
|
Heart Valve Prosthesis | 4 | 2020 | 1466 | 1.120 |
Why?
|
Female | 145 | 2025 | 396101 | 1.110 |
Why?
|
Patient Readmission | 7 | 2024 | 3286 | 1.100 |
Why?
|
Pharmacoepidemiology | 2 | 2024 | 351 | 1.060 |
Why?
|
Anticoagulants | 11 | 2024 | 4862 | 1.050 |
Why?
|
Myocardial Infarction | 11 | 2024 | 11501 | 1.030 |
Why?
|
Erectile Dysfunction | 2 | 2020 | 437 | 0.990 |
Why?
|
Subacute Care | 3 | 2025 | 184 | 0.980 |
Why?
|
Nursing Homes | 8 | 2024 | 1084 | 0.940 |
Why?
|
Warfarin | 7 | 2024 | 1494 | 0.940 |
Why?
|
Health Status Indicators | 2 | 2020 | 966 | 0.910 |
Why?
|
Retrospective Studies | 55 | 2025 | 81515 | 0.880 |
Why?
|
Heart Failure | 11 | 2023 | 11840 | 0.880 |
Why?
|
Disability Evaluation | 5 | 2016 | 1820 | 0.870 |
Why?
|
Dipeptidyl-Peptidase IV Inhibitors | 4 | 2023 | 318 | 0.870 |
Why?
|
Recovery of Function | 5 | 2021 | 2966 | 0.860 |
Why?
|
Platelet Aggregation Inhibitors | 5 | 2024 | 2770 | 0.860 |
Why?
|
International Classification of Diseases | 4 | 2021 | 935 | 0.830 |
Why?
|
Disabled Persons | 5 | 2019 | 1208 | 0.810 |
Why?
|
Propensity Score | 8 | 2024 | 1968 | 0.800 |
Why?
|
Decision Support Techniques | 2 | 2022 | 2003 | 0.760 |
Why?
|
Fee-for-Service Plans | 2 | 2024 | 716 | 0.750 |
Why?
|
Postoperative Complications | 10 | 2024 | 15747 | 0.740 |
Why?
|
Diabetes Mellitus, Type 2 | 12 | 2024 | 12240 | 0.720 |
Why?
|
Sulfonylurea Compounds | 3 | 2023 | 221 | 0.720 |
Why?
|
Risk Factors | 48 | 2024 | 74836 | 0.710 |
Why?
|
Hospital Mortality | 8 | 2024 | 5343 | 0.710 |
Why?
|
Cardiac Surgical Procedures | 5 | 2023 | 3675 | 0.710 |
Why?
|
Coronary Artery Disease | 7 | 2023 | 6546 | 0.700 |
Why?
|
Risk Assessment | 24 | 2024 | 24283 | 0.700 |
Why?
|
Long-Term Care | 1 | 2024 | 629 | 0.690 |
Why?
|
Patient Acceptance of Health Care | 5 | 2025 | 3229 | 0.660 |
Why?
|
Randomized Controlled Trials as Topic | 13 | 2024 | 10383 | 0.660 |
Why?
|
Hospital Records | 1 | 2019 | 93 | 0.660 |
Why?
|
Prospective Studies | 32 | 2024 | 54806 | 0.650 |
Why?
|
Hearing Aids | 1 | 2020 | 58 | 0.650 |
Why?
|
Vascular Malformations | 2 | 2015 | 471 | 0.640 |
Why?
|
Cohort Studies | 23 | 2025 | 41647 | 0.640 |
Why?
|
Medicare Part C | 1 | 2024 | 335 | 0.630 |
Why?
|
Dexmedetomidine | 1 | 2023 | 316 | 0.630 |
Why?
|
Fractures, Bone | 5 | 2023 | 2041 | 0.630 |
Why?
|
Survival Rate | 11 | 2022 | 12795 | 0.620 |
Why?
|
Coronary Artery Bypass | 5 | 2023 | 2186 | 0.620 |
Why?
|
Ventricular Dysfunction, Left | 3 | 2023 | 2136 | 0.620 |
Why?
|
Cognition Disorders | 6 | 2016 | 3967 | 0.620 |
Why?
|
Pemphigoid, Bullous | 1 | 2020 | 109 | 0.620 |
Why?
|
Aging | 8 | 2023 | 8731 | 0.620 |
Why?
|
Ischemic Attack, Transient | 1 | 2023 | 870 | 0.580 |
Why?
|
Community-Acquired Infections | 1 | 2021 | 470 | 0.570 |
Why?
|
Quality of Life | 11 | 2023 | 13461 | 0.560 |
Why?
|
Patient-Centered Care | 2 | 2018 | 1458 | 0.550 |
Why?
|
Health Care Costs | 3 | 2025 | 3242 | 0.550 |
Why?
|
Renal Insufficiency, Chronic | 4 | 2023 | 2310 | 0.550 |
Why?
|
Accidental Falls | 6 | 2023 | 1078 | 0.540 |
Why?
|
Ambulatory Care Facilities | 1 | 2023 | 939 | 0.530 |
Why?
|
Pravastatin | 1 | 2018 | 391 | 0.530 |
Why?
|
Veterans | 7 | 2023 | 2664 | 0.520 |
Why?
|
Phenotype | 9 | 2024 | 16721 | 0.510 |
Why?
|
Haloperidol | 3 | 2023 | 391 | 0.510 |
Why?
|
Treatment Outcome | 36 | 2024 | 65189 | 0.500 |
Why?
|
Rural Population | 5 | 2022 | 2317 | 0.490 |
Why?
|
Surgical Procedures, Operative | 3 | 2024 | 1941 | 0.480 |
Why?
|
Retinal Diseases | 2 | 2011 | 709 | 0.480 |
Why?
|
Health Status | 3 | 2018 | 4080 | 0.480 |
Why?
|
Ticlopidine | 2 | 2009 | 731 | 0.460 |
Why?
|
Cross-Sectional Studies | 18 | 2025 | 26313 | 0.450 |
Why?
|
Thoracic Surgical Procedures | 1 | 2018 | 349 | 0.450 |
Why?
|
Polypharmacy | 3 | 2022 | 306 | 0.450 |
Why?
|
Vulnerable Populations | 2 | 2020 | 718 | 0.440 |
Why?
|
Diphosphonates | 2 | 2016 | 625 | 0.430 |
Why?
|
Mortality | 6 | 2021 | 2904 | 0.430 |
Why?
|
Nutritional Status | 3 | 2018 | 1620 | 0.430 |
Why?
|
Aspirin | 2 | 2019 | 3134 | 0.430 |
Why?
|
Stroke | 8 | 2024 | 9747 | 0.430 |
Why?
|
Patient Admission | 1 | 2021 | 1365 | 0.430 |
Why?
|
Acute Kidney Injury | 3 | 2024 | 1946 | 0.420 |
Why?
|
Syncope | 2 | 2018 | 429 | 0.420 |
Why?
|
Comorbidity | 10 | 2024 | 10563 | 0.420 |
Why?
|
Administration, Oral | 5 | 2024 | 4015 | 0.420 |
Why?
|
Hip Fractures | 4 | 2024 | 997 | 0.420 |
Why?
|
Adrenergic beta-Antagonists | 5 | 2023 | 1237 | 0.410 |
Why?
|
Social Behavior | 1 | 2019 | 1146 | 0.410 |
Why?
|
Bone Density Conservation Agents | 2 | 2022 | 791 | 0.410 |
Why?
|
Drug Prescriptions | 2 | 2020 | 1662 | 0.410 |
Why?
|
Hearing Loss | 1 | 2020 | 784 | 0.400 |
Why?
|
Prognosis | 14 | 2025 | 29921 | 0.400 |
Why?
|
Cognition | 7 | 2021 | 7048 | 0.390 |
Why?
|
Interpersonal Relations | 1 | 2019 | 1432 | 0.380 |
Why?
|
Severity of Illness Index | 11 | 2024 | 15880 | 0.380 |
Why?
|
Geriatrics | 1 | 2016 | 396 | 0.380 |
Why?
|
Life Expectancy | 2 | 2019 | 1247 | 0.380 |
Why?
|
Cause of Death | 3 | 2021 | 3708 | 0.370 |
Why?
|
Anticholesteremic Agents | 1 | 2018 | 970 | 0.370 |
Why?
|
Hemorrhage | 6 | 2024 | 3461 | 0.370 |
Why?
|
Drug Utilization | 1 | 2017 | 1187 | 0.360 |
Why?
|
Kaplan-Meier Estimate | 6 | 2020 | 6499 | 0.360 |
Why?
|
Primary Prevention | 1 | 2018 | 1187 | 0.360 |
Why?
|
Prevalence | 12 | 2023 | 15839 | 0.350 |
Why?
|
Dopamine Agents | 1 | 2011 | 186 | 0.340 |
Why?
|
France | 6 | 2024 | 495 | 0.340 |
Why?
|
Exercise | 4 | 2020 | 5937 | 0.340 |
Why?
|
Nootropic Agents | 1 | 2011 | 159 | 0.340 |
Why?
|
Hospitalization | 12 | 2023 | 10808 | 0.330 |
Why?
|
Checklist | 1 | 2017 | 848 | 0.330 |
Why?
|
Seafood | 1 | 2013 | 395 | 0.330 |
Why?
|
Health Status Disparities | 3 | 2019 | 1880 | 0.330 |
Why?
|
Coronary Artery Bypass, Off-Pump | 1 | 2009 | 65 | 0.330 |
Why?
|
Respiratory Insufficiency | 1 | 2018 | 1240 | 0.330 |
Why?
|
Time Factors | 15 | 2025 | 40065 | 0.330 |
Why?
|
Electronic Health Records | 2 | 2024 | 4873 | 0.330 |
Why?
|
Benzethonium | 1 | 2009 | 6 | 0.320 |
Why?
|
Paromomycin | 1 | 2009 | 14 | 0.320 |
Why?
|
Pyridones | 3 | 2024 | 816 | 0.320 |
Why?
|
Hand Strength | 3 | 2021 | 462 | 0.320 |
Why?
|
Data Interpretation, Statistical | 6 | 2020 | 2686 | 0.310 |
Why?
|
Age Factors | 11 | 2021 | 18380 | 0.310 |
Why?
|
Drug-Eluting Stents | 2 | 2019 | 683 | 0.310 |
Why?
|
Antiprotozoal Agents | 1 | 2009 | 93 | 0.300 |
Why?
|
Pyrazoles | 3 | 2024 | 2033 | 0.300 |
Why?
|
Diabetes Mellitus | 2 | 2023 | 5891 | 0.290 |
Why?
|
Incidence | 9 | 2021 | 21480 | 0.290 |
Why?
|
Depression | 4 | 2023 | 8230 | 0.280 |
Why?
|
Adiponectin | 1 | 2013 | 1119 | 0.280 |
Why?
|
Leishmaniasis, Cutaneous | 1 | 2009 | 137 | 0.280 |
Why?
|
HIV Infections | 3 | 2022 | 17533 | 0.280 |
Why?
|
Health Services for the Aged | 1 | 2009 | 265 | 0.270 |
Why?
|
Algorithms | 5 | 2024 | 14071 | 0.270 |
Why?
|
Cardiology Service, Hospital | 1 | 2008 | 242 | 0.270 |
Why?
|
Comparative Effectiveness Research | 2 | 2023 | 714 | 0.260 |
Why?
|
Canada | 6 | 2024 | 2119 | 0.260 |
Why?
|
Cardiac Output, Low | 1 | 2007 | 192 | 0.260 |
Why?
|
Carotid Artery Diseases | 2 | 2011 | 874 | 0.250 |
Why?
|
Breast Neoplasms | 6 | 2025 | 21056 | 0.250 |
Why?
|
Clinical Trials as Topic | 2 | 2021 | 8041 | 0.250 |
Why?
|
Hypoglycemic Agents | 7 | 2024 | 3110 | 0.250 |
Why?
|
Self Report | 3 | 2022 | 3771 | 0.250 |
Why?
|
Stroke Volume | 6 | 2023 | 5596 | 0.240 |
Why?
|
Odds Ratio | 7 | 2022 | 9649 | 0.240 |
Why?
|
Retinal Vessels | 1 | 2011 | 863 | 0.240 |
Why?
|
Forecasting | 1 | 2014 | 2936 | 0.240 |
Why?
|
Carbonated Beverages | 1 | 2006 | 209 | 0.240 |
Why?
|
Institutionalization | 2 | 2023 | 108 | 0.240 |
Why?
|
Biomedical Research | 2 | 2020 | 3458 | 0.240 |
Why?
|
Terminal Care | 3 | 2021 | 1774 | 0.230 |
Why?
|
Preventive Health Services | 1 | 2009 | 570 | 0.230 |
Why?
|
Shock, Septic | 1 | 2011 | 774 | 0.230 |
Why?
|
Morbidity | 4 | 2023 | 1749 | 0.230 |
Why?
|
Dietary Fats | 2 | 2012 | 2002 | 0.220 |
Why?
|
Coronary Disease | 1 | 2018 | 5912 | 0.220 |
Why?
|
Length of Stay | 4 | 2024 | 6485 | 0.220 |
Why?
|
Central Nervous System Agents | 1 | 2024 | 72 | 0.220 |
Why?
|
Middle Aged | 27 | 2024 | 223004 | 0.220 |
Why?
|
Hypotension | 1 | 2009 | 885 | 0.220 |
Why?
|
Acute Coronary Syndrome | 2 | 2024 | 2184 | 0.220 |
Why?
|
Microcirculation | 3 | 2014 | 1280 | 0.210 |
Why?
|
Receptors, Angiotensin | 1 | 2023 | 141 | 0.210 |
Why?
|
Peripheral Vascular Diseases | 1 | 2006 | 516 | 0.210 |
Why?
|
Survival Analysis | 7 | 2021 | 10070 | 0.210 |
Why?
|
Cerebrovascular Disorders | 1 | 2010 | 1470 | 0.210 |
Why?
|
SEER Program | 2 | 2025 | 1446 | 0.200 |
Why?
|
Advance Care Planning | 2 | 2020 | 702 | 0.200 |
Why?
|
Heart Rate | 3 | 2019 | 4203 | 0.200 |
Why?
|
Databases, Factual | 7 | 2024 | 8067 | 0.200 |
Why?
|
Life Style | 3 | 2024 | 3926 | 0.200 |
Why?
|
Glaucoma | 2 | 2023 | 1194 | 0.200 |
Why?
|
Proportional Hazards Models | 8 | 2022 | 12509 | 0.200 |
Why?
|
Cholesterol, HDL | 2 | 2009 | 1811 | 0.190 |
Why?
|
Models, Statistical | 2 | 2014 | 5089 | 0.190 |
Why?
|
Vitamin K | 1 | 2024 | 312 | 0.190 |
Why?
|
Coffee | 1 | 2006 | 593 | 0.190 |
Why?
|
Melanosis | 1 | 2022 | 93 | 0.190 |
Why?
|
Caffeine | 1 | 2006 | 702 | 0.190 |
Why?
|
Dietary Supplements | 2 | 2018 | 3426 | 0.180 |
Why?
|
Risperidone | 1 | 2023 | 383 | 0.180 |
Why?
|
Colorectal Surgery | 1 | 2023 | 125 | 0.180 |
Why?
|
Demography | 2 | 2016 | 1641 | 0.180 |
Why?
|
Purinergic P2Y Receptor Antagonists | 1 | 2023 | 284 | 0.180 |
Why?
|
Drug Therapy | 1 | 2024 | 504 | 0.180 |
Why?
|
Information Systems | 1 | 2023 | 400 | 0.180 |
Why?
|
Longitudinal Studies | 7 | 2025 | 14749 | 0.180 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2015 | 3251 | 0.170 |
Why?
|
Chemotherapy, Adjuvant | 4 | 2025 | 3537 | 0.170 |
Why?
|
Neprilysin | 1 | 2023 | 484 | 0.170 |
Why?
|
Withholding Treatment | 1 | 2024 | 621 | 0.170 |
Why?
|
Medical Oncology | 3 | 2022 | 2339 | 0.170 |
Why?
|
Predictive Value of Tests | 6 | 2021 | 15398 | 0.170 |
Why?
|
Depressive Disorder | 2 | 2011 | 3710 | 0.170 |
Why?
|
Oxadiazoles | 1 | 2020 | 94 | 0.170 |
Why?
|
Stomach Neoplasms | 2 | 2021 | 1471 | 0.170 |
Why?
|
Embolism | 1 | 2023 | 400 | 0.170 |
Why?
|
Aromatase | 1 | 2020 | 147 | 0.170 |
Why?
|
Alzheimer Disease | 3 | 2023 | 8728 | 0.170 |
Why?
|
Osteoporosis | 2 | 2022 | 1582 | 0.160 |
Why?
|
Hypoglycemia | 2 | 2024 | 896 | 0.160 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 3 | 2023 | 11868 | 0.160 |
Why?
|
Decision Making | 3 | 2018 | 3965 | 0.160 |
Why?
|
Hospitals | 2 | 2023 | 3888 | 0.160 |
Why?
|
Preoperative Care | 2 | 2019 | 2267 | 0.160 |
Why?
|
Consensus | 2 | 2019 | 3202 | 0.160 |
Why?
|
Current Procedural Terminology | 1 | 2020 | 100 | 0.160 |
Why?
|
Exercise Therapy | 1 | 2006 | 937 | 0.160 |
Why?
|
Vitamin D Deficiency | 1 | 2008 | 1348 | 0.160 |
Why?
|
Atrial Appendage | 1 | 2023 | 284 | 0.160 |
Why?
|
Research Design | 4 | 2022 | 6208 | 0.160 |
Why?
|
Telephone | 1 | 2022 | 627 | 0.160 |
Why?
|
Risk | 4 | 2015 | 9591 | 0.160 |
Why?
|
Iceland | 1 | 2019 | 183 | 0.160 |
Why?
|
Trifluridine | 1 | 2019 | 27 | 0.160 |
Why?
|
Walking | 1 | 2006 | 1198 | 0.150 |
Why?
|
Stents | 2 | 2019 | 3213 | 0.150 |
Why?
|
Accidents, Home | 1 | 2018 | 73 | 0.150 |
Why?
|
Habits | 1 | 2019 | 147 | 0.150 |
Why?
|
Inappropriate Prescribing | 1 | 2021 | 211 | 0.150 |
Why?
|
Cholesterol, LDL | 1 | 2007 | 2393 | 0.150 |
Why?
|
Health Behavior | 1 | 2009 | 2650 | 0.150 |
Why?
|
Psychotropic Drugs | 1 | 2023 | 879 | 0.150 |
Why?
|
Wet Macular Degeneration | 1 | 2020 | 164 | 0.150 |
Why?
|
Propanolamines | 1 | 2018 | 163 | 0.140 |
Why?
|
Osteoporotic Fractures | 1 | 2022 | 415 | 0.140 |
Why?
|
Water-Electrolyte Imbalance | 1 | 2018 | 110 | 0.140 |
Why?
|
Benzodiazepines | 1 | 2023 | 1136 | 0.140 |
Why?
|
Critical Care | 2 | 2020 | 2712 | 0.140 |
Why?
|
Muscular Dystrophy, Duchenne | 1 | 2020 | 271 | 0.140 |
Why?
|
Sex Factors | 3 | 2020 | 10602 | 0.140 |
Why?
|
Logistic Models | 5 | 2020 | 13266 | 0.130 |
Why?
|
Confidence Intervals | 3 | 2020 | 2910 | 0.130 |
Why?
|
Stress, Physiological | 1 | 2024 | 1402 | 0.130 |
Why?
|
Task Performance and Analysis | 1 | 2020 | 770 | 0.130 |
Why?
|
Random Allocation | 1 | 2021 | 2395 | 0.130 |
Why?
|
Angiotensin Receptor Antagonists | 1 | 2023 | 1061 | 0.130 |
Why?
|
Postoperative Hemorrhage | 1 | 2020 | 413 | 0.130 |
Why?
|
Residence Characteristics | 3 | 2022 | 2115 | 0.130 |
Why?
|
Systole | 2 | 2009 | 935 | 0.130 |
Why?
|
Evidence-Based Medicine | 2 | 2018 | 3685 | 0.120 |
Why?
|
Hypnotics and Sedatives | 1 | 2023 | 1191 | 0.120 |
Why?
|
Primary Health Care | 1 | 2012 | 4736 | 0.120 |
Why?
|
Nutrition Assessment | 1 | 2018 | 738 | 0.120 |
Why?
|
Healthcare Disparities | 2 | 2021 | 3412 | 0.120 |
Why?
|
Catheterization, Peripheral | 1 | 2018 | 349 | 0.120 |
Why?
|
Vitamin D | 1 | 2008 | 3272 | 0.120 |
Why?
|
Natural Language Processing | 1 | 2024 | 1203 | 0.120 |
Why?
|
Reimbursement Mechanisms | 1 | 2020 | 672 | 0.120 |
Why?
|
Multiple Myeloma | 2 | 2023 | 5197 | 0.120 |
Why?
|
Femoral Artery | 1 | 2018 | 811 | 0.110 |
Why?
|
Bronchi | 1 | 2018 | 843 | 0.110 |
Why?
|
Health Expenditures | 3 | 2023 | 2387 | 0.110 |
Why?
|
Immunotherapy | 2 | 2021 | 4752 | 0.110 |
Why?
|
Anticonvulsants | 1 | 2023 | 1921 | 0.110 |
Why?
|
Ankle Brachial Index | 1 | 2014 | 166 | 0.110 |
Why?
|
Electrocardiography | 2 | 2019 | 6404 | 0.110 |
Why?
|
Respiratory Function Tests | 1 | 2018 | 1693 | 0.110 |
Why?
|
Quality Indicators, Health Care | 2 | 2020 | 1806 | 0.110 |
Why?
|
Cardiovascular Agents | 1 | 2019 | 851 | 0.100 |
Why?
|
Neoplasm Staging | 2 | 2025 | 11206 | 0.100 |
Why?
|
Socioeconomic Factors | 4 | 2022 | 7836 | 0.100 |
Why?
|
Urinary Tract Infections | 1 | 2019 | 805 | 0.100 |
Why?
|
Colorectal Neoplasms | 3 | 2022 | 6942 | 0.100 |
Why?
|
Endothelial Cells | 1 | 2005 | 3584 | 0.100 |
Why?
|
Europe | 1 | 2019 | 3423 | 0.100 |
Why?
|
Stem Cells | 1 | 2005 | 3540 | 0.100 |
Why?
|
Health Surveys | 3 | 2019 | 4056 | 0.100 |
Why?
|
Glucagon-Like Peptide 1 | 3 | 2021 | 373 | 0.100 |
Why?
|
Coronavirus Infections | 2 | 2020 | 3100 | 0.100 |
Why?
|
Macular Degeneration | 1 | 2020 | 1014 | 0.100 |
Why?
|
Anti-Bacterial Agents | 1 | 2011 | 7478 | 0.100 |
Why?
|
Lung Neoplasms | 4 | 2022 | 13451 | 0.100 |
Why?
|
Follow-Up Studies | 6 | 2021 | 39194 | 0.100 |
Why?
|
Pneumonia, Viral | 2 | 2020 | 3223 | 0.100 |
Why?
|
Mobility Limitation | 1 | 2016 | 408 | 0.100 |
Why?
|
Exercise Tolerance | 1 | 2017 | 841 | 0.100 |
Why?
|
Trachea | 1 | 2018 | 1085 | 0.100 |
Why?
|
Malnutrition | 1 | 2018 | 629 | 0.100 |
Why?
|
Neuropsychological Tests | 3 | 2015 | 7122 | 0.100 |
Why?
|
Chronic Disease | 2 | 2024 | 9347 | 0.090 |
Why?
|
Anti-Inflammatory Agents, Non-Steroidal | 1 | 2021 | 2268 | 0.090 |
Why?
|
Drug Interactions | 1 | 2016 | 1417 | 0.090 |
Why?
|
Feasibility Studies | 1 | 2022 | 5302 | 0.090 |
Why?
|
Antidepressive Agents | 1 | 2023 | 2897 | 0.090 |
Why?
|
Esophageal Neoplasms | 1 | 2021 | 1661 | 0.090 |
Why?
|
Postoperative Period | 2 | 2021 | 1816 | 0.090 |
Why?
|
Placebos | 1 | 2015 | 1659 | 0.090 |
Why?
|
Epidemiologic Research Design | 1 | 2014 | 368 | 0.090 |
Why?
|
Hematologic Neoplasms | 1 | 2022 | 1927 | 0.090 |
Why?
|
Exercise Test | 1 | 2018 | 2180 | 0.090 |
Why?
|
Lower Extremity | 1 | 2018 | 1226 | 0.090 |
Why?
|
Pandemics | 2 | 2020 | 8701 | 0.090 |
Why?
|
Neoplasms | 4 | 2022 | 22340 | 0.080 |
Why?
|
Quality Improvement | 2 | 2022 | 3853 | 0.080 |
Why?
|
Program Evaluation | 1 | 2018 | 2499 | 0.080 |
Why?
|
Pain | 2 | 2023 | 5077 | 0.080 |
Why?
|
Quality Assurance, Health Care | 1 | 2020 | 2172 | 0.080 |
Why?
|
Selection Bias | 1 | 2011 | 361 | 0.080 |
Why?
|
Adaptation, Physiological | 1 | 2016 | 1308 | 0.080 |
Why?
|
Diagnostic Techniques, Ophthalmological | 1 | 2011 | 252 | 0.080 |
Why?
|
Imidazoles | 1 | 2015 | 1162 | 0.080 |
Why?
|
Adult | 10 | 2022 | 223038 | 0.080 |
Why?
|
Patient Preference | 1 | 2016 | 952 | 0.080 |
Why?
|
Heart Diseases | 1 | 2021 | 2821 | 0.080 |
Why?
|
Sweet Syndrome | 1 | 2009 | 59 | 0.070 |
Why?
|
Massachusetts | 1 | 2021 | 8871 | 0.070 |
Why?
|
Psychiatric Status Rating Scales | 1 | 2018 | 6014 | 0.070 |
Why?
|
Interviews as Topic | 1 | 2016 | 2739 | 0.070 |
Why?
|
Pennsylvania | 1 | 2009 | 614 | 0.070 |
Why?
|
Retinol-Binding Proteins, Plasma | 1 | 2008 | 94 | 0.070 |
Why?
|
Urban Population | 1 | 2016 | 2040 | 0.070 |
Why?
|
Neoadjuvant Therapy | 1 | 2019 | 2895 | 0.070 |
Why?
|
Blood Pressure Monitoring, Ambulatory | 1 | 2009 | 254 | 0.070 |
Why?
|
Adverse Drug Reaction Reporting Systems | 1 | 2011 | 497 | 0.070 |
Why?
|
United States Food and Drug Administration | 1 | 2016 | 1672 | 0.070 |
Why?
|
Diastole | 1 | 2009 | 785 | 0.070 |
Why?
|
Abdominal Fat | 1 | 2009 | 217 | 0.070 |
Why?
|
Hospitals, Rural | 1 | 2008 | 175 | 0.070 |
Why?
|
Employment | 1 | 2013 | 1106 | 0.070 |
Why?
|
Colonic Neoplasms | 1 | 2018 | 2531 | 0.070 |
Why?
|
Leptin | 1 | 2015 | 1596 | 0.070 |
Why?
|
Hospitals, Urban | 1 | 2008 | 493 | 0.070 |
Why?
|
Poverty | 1 | 2018 | 2714 | 0.070 |
Why?
|
Injections, Intravenous | 1 | 2009 | 1377 | 0.070 |
Why?
|
Body Composition | 1 | 2016 | 2439 | 0.070 |
Why?
|
Memory | 2 | 2013 | 2190 | 0.070 |
Why?
|
PPAR gamma | 1 | 2009 | 483 | 0.060 |
Why?
|
Eating | 1 | 2013 | 1539 | 0.060 |
Why?
|
Pentoxifylline | 1 | 2006 | 54 | 0.060 |
Why?
|
Sweden | 1 | 2009 | 1381 | 0.060 |
Why?
|
Head and Neck Neoplasms | 1 | 2020 | 2921 | 0.060 |
Why?
|
Gene Expression | 1 | 2018 | 7584 | 0.060 |
Why?
|
Patient Compliance | 1 | 2016 | 2692 | 0.060 |
Why?
|
Aftercare | 2 | 2023 | 911 | 0.060 |
Why?
|
Hematopoietic Stem Cell Mobilization | 1 | 2006 | 227 | 0.060 |
Why?
|
Analgesics, Opioid | 1 | 2021 | 3835 | 0.060 |
Why?
|
Educational Status | 1 | 2012 | 2513 | 0.060 |
Why?
|
Lung | 1 | 2023 | 10033 | 0.060 |
Why?
|
Frontal Lobe | 1 | 2011 | 1409 | 0.060 |
Why?
|
Fatty Acids, Unsaturated | 1 | 2007 | 538 | 0.060 |
Why?
|
Community Health Services | 1 | 2009 | 657 | 0.060 |
Why?
|
Osteoarthritis, Knee | 1 | 2015 | 1248 | 0.060 |
Why?
|
Safety | 1 | 2009 | 1157 | 0.060 |
Why?
|
Blood Glucose | 2 | 2009 | 6425 | 0.060 |
Why?
|
Vasodilation | 1 | 2008 | 970 | 0.060 |
Why?
|
Thiazides | 1 | 2023 | 19 | 0.060 |
Why?
|
Psoas Muscles | 1 | 2024 | 66 | 0.060 |
Why?
|
Body Weight | 1 | 2015 | 4622 | 0.060 |
Why?
|
Sensitivity and Specificity | 1 | 2019 | 14652 | 0.060 |
Why?
|
Granulocyte Colony-Stimulating Factor | 1 | 2006 | 633 | 0.050 |
Why?
|
Intermittent Claudication | 1 | 2006 | 300 | 0.050 |
Why?
|
Amlodipine | 1 | 2023 | 84 | 0.050 |
Why?
|
Antigens, CD34 | 1 | 2005 | 656 | 0.050 |
Why?
|
Women's Health | 1 | 2013 | 2084 | 0.050 |
Why?
|
Diabetic Angiopathies | 1 | 2008 | 805 | 0.050 |
Why?
|
Smoking | 2 | 2011 | 9081 | 0.050 |
Why?
|
Social Class | 2 | 2022 | 2007 | 0.050 |
Why?
|
Body Mass Index | 4 | 2018 | 13039 | 0.050 |
Why?
|
Statistics as Topic | 2 | 2020 | 2352 | 0.050 |
Why?
|
Case-Control Studies | 1 | 2020 | 22222 | 0.050 |
Why?
|
Hypopigmentation | 1 | 2022 | 43 | 0.050 |
Why?
|
Public Health | 2 | 2020 | 2680 | 0.050 |
Why?
|
Sleep Deprivation | 1 | 2009 | 845 | 0.050 |
Why?
|
Dyslipidemias | 1 | 2009 | 869 | 0.050 |
Why?
|
Drug Substitution | 1 | 2024 | 292 | 0.050 |
Why?
|
Pancreatic Neoplasms | 1 | 2019 | 5444 | 0.050 |
Why?
|
Autonomic Nervous System | 1 | 2006 | 706 | 0.050 |
Why?
|
Drug Therapy, Combination | 1 | 2011 | 6309 | 0.050 |
Why?
|
Transportation | 1 | 2022 | 217 | 0.050 |
Why?
|
Multivariate Analysis | 1 | 2014 | 12057 | 0.040 |
Why?
|
Glucose | 2 | 2023 | 4335 | 0.040 |
Why?
|
Dexamethasone | 2 | 2023 | 1963 | 0.040 |
Why?
|
Anti-Arrhythmia Agents | 1 | 2024 | 769 | 0.040 |
Why?
|
Tetrazoles | 1 | 2006 | 920 | 0.040 |
Why?
|
Fatty Acids | 1 | 2007 | 1806 | 0.040 |
Why?
|
Obesity | 2 | 2015 | 13075 | 0.040 |
Why?
|
Melanoma | 1 | 2018 | 5719 | 0.040 |
Why?
|
Homes for the Aged | 1 | 2021 | 273 | 0.040 |
Why?
|
Decision Trees | 1 | 2021 | 509 | 0.040 |
Why?
|
Skin Neoplasms | 1 | 2018 | 5849 | 0.040 |
Why?
|
Emergency Service, Hospital | 1 | 2018 | 7875 | 0.040 |
Why?
|
Thymine | 1 | 2019 | 69 | 0.040 |
Why?
|
Reproducibility of Results | 1 | 2017 | 20125 | 0.040 |
Why?
|
Adenosine Monophosphate | 1 | 2020 | 231 | 0.040 |
Why?
|
Myelodysplastic Syndromes | 1 | 2009 | 1403 | 0.040 |
Why?
|
Wounds and Injuries | 1 | 2011 | 2511 | 0.040 |
Why?
|
Intravitreal Injections | 1 | 2020 | 401 | 0.040 |
Why?
|
Immunization, Passive | 1 | 2020 | 616 | 0.040 |
Why?
|
Home Care Services | 1 | 2024 | 660 | 0.040 |
Why?
|
Alanine | 1 | 2020 | 612 | 0.040 |
Why?
|
New York | 1 | 2020 | 880 | 0.040 |
Why?
|
Lipids | 1 | 2008 | 3316 | 0.040 |
Why?
|
Pyrrolidines | 1 | 2019 | 337 | 0.030 |
Why?
|
Angiotensin-Converting Enzyme Inhibitors | 1 | 2023 | 1514 | 0.030 |
Why?
|
Absorbable Implants | 1 | 2019 | 333 | 0.030 |
Why?
|
Intensive Care Units | 2 | 2020 | 3800 | 0.030 |
Why?
|
C-Reactive Protein | 1 | 2008 | 3850 | 0.030 |
Why?
|
Environment | 1 | 2022 | 1114 | 0.030 |
Why?
|
Aminopyridines | 1 | 2020 | 576 | 0.030 |
Why?
|
Endothelium, Vascular | 1 | 2008 | 4427 | 0.030 |
Why?
|
Acute Disease | 1 | 2007 | 7232 | 0.030 |
Why?
|
Gastrointestinal Hemorrhage | 1 | 2023 | 1127 | 0.030 |
Why?
|
United States Department of Veterans Affairs | 1 | 2021 | 934 | 0.030 |
Why?
|
Aromatase Inhibitors | 1 | 2020 | 518 | 0.030 |
Why?
|
Factor Analysis, Statistical | 1 | 2018 | 999 | 0.030 |
Why?
|
Sodium | 1 | 2021 | 1591 | 0.030 |
Why?
|
North America | 1 | 2019 | 1285 | 0.030 |
Why?
|
Erythrocyte Transfusion | 1 | 2020 | 568 | 0.030 |
Why?
|
Benzimidazoles | 1 | 2020 | 864 | 0.030 |
Why?
|
Probability | 1 | 2020 | 2475 | 0.030 |
Why?
|
Endpoint Determination | 1 | 2017 | 591 | 0.030 |
Why?
|
Deoxycytidine | 1 | 2019 | 889 | 0.030 |
Why?
|
Health Knowledge, Attitudes, Practice | 1 | 2009 | 4058 | 0.030 |
Why?
|
Area Under Curve | 1 | 2018 | 1638 | 0.030 |
Why?
|
Reoperation | 1 | 2024 | 4294 | 0.030 |
Why?
|
Clinical Trials, Phase III as Topic | 1 | 2018 | 878 | 0.030 |
Why?
|
Cross-Over Studies | 1 | 2020 | 2108 | 0.030 |
Why?
|
Estrogens | 1 | 2020 | 1529 | 0.030 |
Why?
|
Multicenter Studies as Topic | 1 | 2018 | 1731 | 0.030 |
Why?
|
Stress, Psychological | 1 | 2008 | 4533 | 0.030 |
Why?
|
Glomerular Filtration Rate | 1 | 2021 | 2233 | 0.030 |
Why?
|
Lymphocytes, Tumor-Infiltrating | 1 | 2018 | 1106 | 0.030 |
Why?
|
Drug Combinations | 1 | 2019 | 2077 | 0.020 |
Why?
|
Academic Medical Centers | 1 | 2023 | 2780 | 0.020 |
Why?
|
Sirolimus | 1 | 2019 | 1545 | 0.020 |
Why?
|
Polymers | 1 | 2019 | 1621 | 0.020 |
Why?
|
Double-Blind Method | 2 | 2019 | 12437 | 0.020 |
Why?
|
Bone Density | 1 | 2024 | 3491 | 0.020 |
Why?
|
Medication Adherence | 1 | 2022 | 2190 | 0.020 |
Why?
|
Caregivers | 1 | 2023 | 2307 | 0.020 |
Why?
|
Women | 1 | 2012 | 226 | 0.020 |
Why?
|
Postural Balance | 1 | 2015 | 637 | 0.020 |
Why?
|
Angiogenesis Inhibitors | 1 | 2020 | 2056 | 0.020 |
Why?
|
Receptor, erbB-2 | 1 | 2020 | 2593 | 0.020 |
Why?
|
Attention | 1 | 2020 | 2418 | 0.020 |
Why?
|
Korea | 1 | 2009 | 97 | 0.020 |
Why?
|
Insulin | 1 | 2023 | 6599 | 0.020 |
Why?
|
Vascular Endothelial Growth Factor A | 1 | 2020 | 3513 | 0.020 |
Why?
|
Inpatients | 1 | 2020 | 2564 | 0.020 |
Why?
|
Hypertension, Pulmonary | 1 | 2019 | 1604 | 0.020 |
Why?
|
Prednisolone | 1 | 2009 | 324 | 0.020 |
Why?
|
Young Adult | 3 | 2009 | 59886 | 0.020 |
Why?
|
Critical Illness | 1 | 2020 | 2744 | 0.020 |
Why?
|
Health Personnel | 1 | 2021 | 3390 | 0.020 |
Why?
|
Molecular Targeted Therapy | 1 | 2018 | 2822 | 0.020 |
Why?
|
Magnetic Resonance Imaging | 1 | 2014 | 36532 | 0.020 |
Why?
|
Remission Induction | 1 | 2012 | 2411 | 0.020 |
Why?
|
Antineoplastic Agents | 2 | 2020 | 13648 | 0.020 |
Why?
|
Neoplasm Proteins | 1 | 2018 | 3596 | 0.020 |
Why?
|
Thiazolidinediones | 1 | 2009 | 459 | 0.020 |
Why?
|
Ventricular Function, Left | 1 | 2019 | 3928 | 0.020 |
Why?
|
Regression Analysis | 1 | 2015 | 6321 | 0.020 |
Why?
|
Carcinoma, Renal Cell | 1 | 2020 | 3181 | 0.010 |
Why?
|
Health Services Accessibility | 1 | 2022 | 5506 | 0.010 |
Why?
|
Waist Circumference | 1 | 2009 | 933 | 0.010 |
Why?
|
Delivery of Health Care | 1 | 2023 | 5369 | 0.010 |
Why?
|
Clinical Competence | 1 | 2020 | 4863 | 0.010 |
Why?
|
Kidney Neoplasms | 1 | 2020 | 4274 | 0.010 |
Why?
|
Infant, Newborn | 1 | 2023 | 26349 | 0.010 |
Why?
|
Cell Adhesion Molecules | 1 | 2008 | 1612 | 0.010 |
Why?
|
Protein Kinase Inhibitors | 1 | 2018 | 5696 | 0.010 |
Why?
|
Neoplasm Recurrence, Local | 1 | 2020 | 9373 | 0.010 |
Why?
|
Triglycerides | 1 | 2009 | 2441 | 0.010 |
Why?
|
Tomography, X-Ray Computed | 1 | 2024 | 20660 | 0.010 |
Why?
|
Treatment Failure | 1 | 2006 | 2652 | 0.010 |
Why?
|
Boston | 1 | 2012 | 9338 | 0.010 |
Why?
|
Glucocorticoids | 1 | 2009 | 2132 | 0.010 |
Why?
|
Ultrasonography | 1 | 2008 | 5993 | 0.010 |
Why?
|
Insulin Resistance | 1 | 2008 | 3985 | 0.010 |
Why?
|
Heart | 1 | 2006 | 4414 | 0.010 |
Why?
|